Blume Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Blume Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50	Closed	-$28K	–	307
2021 Q2	$28K	Hold	50	–	–	0.01%	199
2021 Q1	$24K	Buy	+50	New	+$24.3K	0.01%	196
2019 Q4	–	Sell	-50	Closed	-$13K	–	235
2019 Q3	$13K	Hold	50	–	–	0.01%	178
2019 Q2	$16K	Hold	50	–	–	0.01%	163
2019 Q1	$21K	Sell	50 -46	-48%	-$18.9K	0.01%	160
2018 Q4	$36K	Buy	+96	New	+$35.1K	0.02%	136
2018 Q2	–	Sell	-95	Closed	-$32K	–	216
2018 Q1	$32K	Hold	95	–	–	0.02%	138
2017 Q4	$36K	Hold	95	–	–	0.02%	142
2017 Q3	$42K	Buy	+95	New	+$45.2K	0.02%	128
2016 Q2	–	Sell	-100	Closed	-$36K	–	239
2016 Q1	$36K	Hold	100	–	–	0.02%	116
2015 Q4	$54K	Hold	100	–	–	0.04%	97
2015 Q3	$47K	Hold	100	–	–	0.04%	97
2015 Q2	$51K	Sell	100 -30	-23%	-$14.6K	0.04%	109
2015 Q1	$59K	Hold	130	–	–	0.04%	122
2014 Q4	$53K	Buy	+130	New	+$51.1K	0.04%	131

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Blume Capital Management's REGN Position: Q3 2021 in Review

Blume Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 50 shares — an estimated $28K sold.

Blume Capital Management first reported a position in REGN in Q4 2014 and held it in 15 quarters. The position peaked at $59K in Q1 2015. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Blume Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Blume Capital Management sold 50 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $28K.
Blume Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 15 quarters.
Blume Capital Management's Regeneron Pharmaceuticals position peaked at $59K in Q1 2015.
1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Blume Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.